<DOC>
	<DOCNO>NCT02492607</DOCNO>
	<brief_summary>A substantial number DCIS lesion never form health hazard , particularly concern slow-growing low-grade DCIS . This imply many woman might unnecessarily go intensive treatment result decrease quality life increase health care cost , without survival benefit . The LORD ( LOw Risk DCIS ) study randomize , international , multicenter , phase III non-inferiority trial , aim determine whether screen-detected low-grade DCIS safely manage active surveillance strategy conventional treatment , either WLE alone , WLE + RT , mastectomy , possibly HT , remain standard care .</brief_summary>
	<brief_title>Management Low-risk DCIS</brief_title>
	<detailed_description />
	<criteria>Women age &gt; = 45 year . Any menopausal status . Calcifications lesion , detect populationbased opportunistic screening mammography . Representative vacuumassisted core biopsy pure lowgrade DCIS Any size DCIS . Marker placement biopsy site ( ) breast . Good correlation pathological radiological finding i.e . finding confirm lowgrade DCIS suspicion intermediate highgrade DCIS invasive breast cancer Prior surgery ipsilateral breast benign lesion allow . ASA score 1 2 Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation Presence mass , increase density around calcification , architectural distortion , stellate lesion mammography . Presence bilateral DCIS . Presence Paget 's disease , invasive breast cancer , lobular carcinoma situ cytology histology . Presence symptomatic DCIS e.g . DCIS detect palpation nipple discharge . Presence synchronous invasive carcinoma contralateral breast . Prior history invasive breast cancer DCIS . Prior history cancer except carcinoma situ cervix basocellular carcinoma skin . Presence serious disease precludes definitive surgical treatment ( e.g . cardiovascular/pulmonary/renal disease ) . Individual family know BRCA1/2 mutation Presence pregnancy breastfeed . Presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Women</keyword>
	<keyword>DCIS</keyword>
	<keyword>Active surveillance</keyword>
	<keyword>Standard treatment</keyword>
</DOC>